Stock listing

Frankfurt:G49N GenSight Biologics SA Aktie

German listing (Frankfurt) of GenSight Biologics SA · home listing Euronext:SIGHT

Follow GenSight Biologics SA into a list and get an email when it puts out news.

Share price · FWB:G49N

€0.063 EUR +0.001 (+1.1%)

Close on Nov 9, 2026

Past year -49.6% · daily closes, Nov 10, 2025 – Nov 6, 2026, adjusted for splits
Day range
€0.063 – €0.063 EURNov 9, 2026
Market cap
€15.38M EURAt the close on Nov 9, 2026 · price × 245.3M shares outstanding
52-week range
€0.049 – €0.127 EURLowest and highest trades, Nov 10, 2025 – Nov 9, 2026
Traded on an average day
€8,564 EURMedian day 0 shares · 47 days with no trades · last 3 months, Aug 10, 2026 – Nov 6, 2026
GenSight Biologics SA logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Euronext:SIGHT · Home€0.077 EUR+0.008 (+11.8%)1,092,977€0.069€0.082€0.069€0.069Close on Nov 9, 2026
LSE:0RIM€0.078 EUR+0.008 (+11.5%)389,259€0.069€0.080€0.069€0.070Close on Nov 9, 2026
Frankfurt:G49N€0.063 EUR+0.001 (+1.1%)—€0.063€0.063€0.063€0.062Close on Nov 9, 2026

Daily closes

Last 3 months, Aug 10, 2026 – Nov 6, 2026 · FWB:G49N · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€0.062-0.001-1.6%€0.062€0.062€0.0620
€0.063-0.001-1.6%€0.063€0.063€0.063330,176
€0.064-0.002-3.0%€0.064€0.064€0.064330,176
€0.066-0.004-5.7%€0.066€0.066€0.0660
€0.070+0.003+4.5%€0.070€0.070€0.0700
€0.067-0.001-1.5%€0.067€0.067€0.067774,656
€0.068+0.002+3.0%€0.068€0.068€0.06879,782
€0.066+0.001+1.5%€0.066€0.066€0.066350,426
€0.065+0.002+3.2%€0.065€0.065€0.0650
€0.063+0.011+21.2%€0.063€0.063€0.06388,200
€0.0520.0000.0%€0.052€0.052€0.05282,788
€0.052-0.002-3.7%€0.052€0.052€0.0520
€0.054+0.003+5.9%€0.054€0.054€0.0540
€0.051-0.002-3.8%€0.051€0.051€0.0510
€0.053-0.002-3.6%€0.053€0.053€0.0530
€0.055+0.005+10.0%€0.055€0.055€0.0550
€0.050+0.001+2.0%€0.050€0.050€0.0500
€0.049-0.005-9.3%€0.049€0.049€0.0490
€0.054-0.002-3.6%€0.054€0.054€0.0540
€0.056-0.017-23.3%€0.056€0.056€0.0560
€0.073-0.002-2.7%€0.073€0.073€0.07374,004
€0.075+0.002+2.7%€0.075€0.075€0.075406,062
€0.0730.0000.0%€0.073€0.073€0.0730
€0.073-0.027-27.0%€0.073€0.073€0.0730
€0.100+0.041+69.5%€0.077€0.101€0.0775,000
€0.059-0.018-23.4%€0.059€0.059€0.059247,530
€0.077-0.011-12.5%€0.077€0.077€0.0770
€0.088-0.011-11.1%€0.088€0.088€0.0880
€0.099-0.004-3.9%€0.099€0.099€0.0990
€0.103-0.017-14.2%€0.103€0.103€0.1030
€0.120+0.002+1.7%€0.120€0.120€0.1201,440,994
€0.118+0.014+13.5%€0.118€0.118€0.1180
€0.104+0.005+5.1%€0.104€0.104€0.1040
€0.0990.0000.0%€0.099€0.099€0.0990
€0.0990.0000.0%€0.099€0.099€0.0990
€0.099-0.001-1.0%€0.099€0.099€0.09999,686
€0.100-0.008-7.4%€0.100€0.100€0.1000
€0.108+0.001+0.9%€0.108€0.108€0.1080
€0.107+0.007+7.0%€0.107€0.107€0.1070
€0.100-0.001-1.0%€0.100€0.100€0.1000
€0.1010.0000.0%€0.101€0.101€0.101273,300
€0.101-0.002-1.9%€0.101€0.101€0.1010
€0.103+0.007+7.3%€0.103€0.103€0.1030
€0.096+0.001+1.1%€0.096€0.096€0.0960
€0.095-0.003-3.1%€0.095€0.095€0.0950
€0.098-0.008-7.5%€0.098€0.098€0.098144,382
€0.106-0.003-2.8%€0.106€0.106€0.1060
€0.109-0.003-2.7%€0.109€0.109€0.1090
€0.112-0.001-0.9%€0.112€0.112€0.1120
€0.113-0.002-1.7%€0.113€0.113€0.1130
€0.115+0.008+7.5%€0.115€0.115€0.115324,200
€0.107-0.002-1.8%€0.107€0.107€0.1070
€0.109-0.003-2.7%€0.109€0.109€0.1090
€0.112+0.009+8.7%€0.112€0.112€0.1120
€0.103+0.008+8.4%€0.103€0.103€0.1030
€0.095-0.002-2.1%€0.095€0.095€0.095765,608
€0.097+0.001+1.0%€0.097€0.097€0.0970
€0.096-0.007-6.8%€0.096€0.096€0.0960
€0.103+0.011+12.0%€0.103€0.103€0.1030
€0.092+0.024+35.3%€0.092€0.092€0.0920
€0.068-0.009-11.7%€0.068€0.068€0.068571,830
€0.0770.0000.0%€0.077€0.077€0.0770
€0.077-0.002-2.5%€0.077€0.077€0.0770
€0.0790.0000.0%€0.079€0.079€0.0790
€0.079-0.001-1.3%€0.079€0.079€0.0790
Ticker
Frankfurt:G49N
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

GenSight Biologics Announces the Closing of its €1.0 Million Fundraising Supported by Existing Shareholders

Oct 16, 2026

Closed €0.053 (-3.6%) on Oct 19, 2026

Gensight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa

Oct 8, 2026

Closed €0.075 (+2.7%) on Oct 8, 2026

GenSight Biologics Announces a Successful €1.0 Million Fundraising Supported by Existing Shareholders

Oct 8, 2026

Closed €0.075 (+2.7%) on Oct 8, 2026

GenSight Biologics Reports Cash Position as of September 30, 2026

Oct 7, 2026

Closed €0.075 (+2.7%) on Oct 8, 2026

GenSight Biologics S A Reports Cash Position as of September 30, 2026

Oct 7, 2026

Closed €0.075 (+2.7%) on Oct 8, 2026

GenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business Updates

Sep 30, 2026

Closed €0.088 (-11.1%) on Sep 30, 2026

GenSight Biologics publie ses résultats financiers du premier semestre 2026 et fait un point sur son activité

Sep 30, 2026

Closed €0.088 (-11.1%) on Sep 30, 2026

GenSight Biologics Provides September 2026 Business Updates

Sep 8, 2026

Closed €0.096 (+1.1%) on Sep 8, 2026

GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates

Jul 8, 2026

Closed €0.076 (+2.7%) on Jul 9, 2026

GenSight Biologics Announces the Results of its Combined General Meeting of May 19, 2026

May 20, 2026

Closed €0.08 (+2.6%) on May 21, 2026

All GenSight Biologics SA news

Financings

  • Private placement of ordinary shares, pre-funded warrants and investor warrants

    Oct 16, 2026

    Closed: €1M in the latest tranche · €0.077 a share · Warrants at €0.0497 for 60 months

    Buyers: Heights Capital; Invus

    Use of proceeds: Operating activities and working capital pending the structural financing of the RECOVER Phase III trial

    Closed Oct 8, 2026 · Closed Oct 16, 2026

  • Private placement of ordinary shares, pre-funded warrants and investor warrants

    Jan 7, 2026 · US$3.38M

    Closed: €2.89M raised · €0.08 a share · Warrants at €0.11 for 60 months

    Buyers: Heights Capital; Invus; Alumni Capital

    Use of proceeds: About 73% to develop GS010/LUMEVOQ; balance for financial obligations incl. EUR 0.7m convertible bond redemption

    Announced Dec 29, 2025 · Closed Jan 7, 2026

  • Private placement of ordinary shares, pre-funded warrants and investor warrants

    Nov 13, 2025 · US$2.33M

    Closed: €2M raised · €0.1045 a share · Warrants at €0.21 for 56 months · Maxim Group, LLC

    Dealers: Maxim Group, LLC

    Buyers: Invus (existing shareholder; 13.3% of share capital after issuance of the Offered Shares); Alumni Capital (existing shareholder; 7.5% of share capital after issuance of the Offered Shares)

    Use of proceeds: Up to about 92% of net proceeds to fund continued development of GS010/LUMEVOQ, including tech transfer, regulatory work and study preparations

    Announced Nov 10, 2025 · Closed Nov 13, 2025

  • Private placement of ordinary shares, pre-funded warrants and investor warrants

    Oct 1, 2025 · US$4.34M

    Closed: €3.69M raised · €0.12 a share · Warrants at €0.21 for 58 months · Maxim Group, LLC

    Dealers: Maxim Group, LLC

    Buyers: Heights Capital (subscription of EUR 0.7 million offset against repayment of convertible bond principal); Invus; Alumni Capital

    Use of proceeds: EUR 0.7 million used to repay principal on convertible bonds held by Heights Capital through offset against their subscription

    Announced Sep 26, 2025 · Closed Oct 1, 2025

  • Private placement of ordinary shares, pre-funded warrants and investor warrants

    Jul 3, 2025 · US$4.59M

    Closed: €3.91M raised · €0.17 a share · Warrants at €0.21 for 60 months · Maxim Group, LLC

    Dealers: Maxim Group, LLC (lead)

    Buyers: Heights Capital (EUR 0.7 million subscription offset against repayment of convertible bonds)

    Use of proceeds: EUR 0.7 million used to repay principal on convertible bonds held by Heights Capital

    Announced Jul 1, 2025 · Closed Jul 3, 2025

Read by 6ix AI from the company's releases

Decks

GenSight Biologics SA on 6ix

Sector
Health care
Industry
Biotechnology
News releases
34 in the last 12 months · 48 in all · newest Oct 16, 2026 · oldest 2025
Decks
20 decks · latest May 19, 2026

Where GenSight Biologics SA is listed

ListingExchangeCountryCurrency
Euronext:SIGHT · Home listingEuronextFranceEUR
LSE:0RIMLSEUnited KingdomEUR
gettex:G49NgettexGermanyEUR
LS Exchange:A2ANGZLS ExchangeGermanyEUR
Lang & Schwarz:A2ANGZLang & SchwarzGermanyEUR
Aquis:SIGHTPAquisUnited KingdomEUR
OTC:GSGTFOTCUnited StatesUSD
Aquis:SIGHTPAquisUnited KingdomEUR
Dusseldorf:G49NDusseldorfGermanyEUR
Frankfurt:G49N · This pageFrankfurtGermanyEUR
Hamburg:G49NHamburgGermanyEUR
Munich:G49NMunichGermanyEUR
Stuttgart:G49NStuttgartGermanyEUR
Turquoise:SIGHTPTurquoiseUnited KingdomEUR

Log in to ask 6ix AI your own questions about GenSight Biologics SA.